3 results
1. The primary objectives of this phase I/II clinical trial is to demonstrate feasibility and evaluate the safety and toxicity of ACT plus vaccination according to CTCAE 4.0 criteria.2. Secondary objectives include the evaluation of the clinical…
Earlier studies suggest that Gaviscon alters the position of the acid pocket, as the number of acid reflux episodes decreased but the number of nonacid reflux events almost doubled after drug intake. (8) However, until now the formation of the raft…
To evaluate the safety and toxicity of ACT and low-dose IFN-alpha plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that do not result in treatment termination are considered acceptable for…